secwatch.observer — SEC 8-K summary
======================================

Issuer:     Krystal Biotech, Inc. (KRYS)
CIK:        0001711279
Form:       8-K
Filed at:   2025-05-13T23:59:59+00:00
Accession:  0001711279-25-000048
Event type: other_material
Sentiment:  positive
Materiality: 0.45
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Krystal Biotech presents preclinical data for KB111 (HHD) and KB112 (Darier) at SID 2025
--------------------------------------------------------------------------------

- KB111 targets ATP2C1 for Hailey-Hailey disease; KB112 targets ATP2A2 for Darier disease.
- Both HSV-1-based vectors transduced keratinocytes with dose-dependent target protein expression and no cytotoxicity.
- KB111 functionally corrected ATP2C1 siRNA knockdown in keratinocytes, reversing F-actin loss (p<0.05).
- Topical administration in mice showed proper localization of ATP2C1 and ATP2A2 with minimal toxicity.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1711279/000171127925000048/0001711279-25-000048-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1711279/000171127925000048/krys-20250512.htm
  HTML page:      https://secwatch.observer/filing/0001711279-25-000048

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer